Jichun Ma, PhD

Jichun Ma, PhD has worked in the biotechnology industry since 2003. From 2003 to 2005, they were a Research Fellow at the National Cancer Institute (NCI) where they established a pichia expression system for production of difficult proteins, including P type ATPases, transmembrane protein TMEM205, and human and mouse P-glycoprotein (P-gp). Jichun also conducted independent studies to investigate the structural and mechanistic insights of the recognition of mesothelin by the therapeutic antibody MORAb-009 and the P-gp transporter pathway. From 2005 to 2011, they were a Sr. Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson, where they served as a protein science expert in supporting numerous pipeline projects across therapeutic areas for drug discovery. From 2011 to 2017, they were a Consultant and Research Scholar at the Cleveland Clinic, where they led projects on the structures and functions of filamin A and its binding partners. Since 2018, they have been working at SPARX THERAPEUTICS as a Director and Associate Director, leading teams in antibody discovery, process development, protein expression and purification, and downstream antibody production.

Jichun Ma, PhD obtained a Doctor of Philosophy (PhD) in Biochemistry from Kyushu University in 2000. Prior to that, they obtained a BM in Public Health from China Medical University.